Skip to content

U-100 unit conversion

P21 / Peptide 021 (Supplier identity) calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

2U-100 units · 0.02 mL

125 mcg per unit · 12500 mcg/mL

That draw is under 5 units, so the barrel is easy to misread. Check your inputs and measuring equipment with a qualified professional. The page does not select a dose or preparation.

How the calculator works, sources and review dates

P21 / Peptide 021 (Supplier identity) math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 25 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-10. source-curated; clinician review pending.

Units chart for listed P21 / Peptide 021 (Supplier identity) sizes

U-100 math for listed P21 / Peptide 021 (Supplier identity) sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
25 mg25012583.3
50 mg500250166.7

What is P21 / Peptide 021 (Supplier identity)?

Other names in the library: P-21, Peptide 021, P21 Peptide Spray — 25mg / Non-Lyophilized, P21 Peptide Spray — 50mg / Non-Lyophilized, P21, Peptide 021, P21 / Peptide 021. P21, P021 and a supplier formulation must be checked by sequence and modification; a product name alone is insufficient. Listed sizes: 25 mg, 50 mg. A seller title is a listing. It does not prove the vial matches a paper.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Lab or animal research

P021 primary study · PMID 28655344

Female3xTg-AD mice and wild-type controls; behavioral and tissue-analysis groups separate.

Reported findings. Improved spatial/object-location memory and selected neurogenesis, dendritic and synaptic markers were reported.

Nonresponse. Nine-month MAP2 deficit was not prevented; cortical synaptophysin active-versus-vehicle difference was nonsignificant.

Harms. Authors report no weight loss, tumors or signs of pain during approximately18months in mice; no human safety assessment.

Limits. P21/P021 equivalence unresolved. Long preventive mouse treatment does not establish human efficacy or route transfer.

Preparation: Experimental P021: CNTF-derived DGGL with adamantylated glycine, N-terminal acetylation and C-terminal amide; not a verified generic P21 preparation. Route: Oral mouse-feed exposure from age3 through21months; not a human or nasal outcome.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Human report

P-21 experience: mixed subjective effects with panic and stimulation

One anonymous public firsthand reporter; preparation and outcomes not independently verified.

Reported findings. Reporter perceived improved mood/energy, reward from ordinary tasks, motivation and sleep. Perceived regeneration is subjective language, not verified tissue or neuronal repair.

Nonresponse. No nonresponse described in inspected account; absence of reporting does not establish absence of an effect.

Harms. Reporter described an acute panic episode with racing heart lasting about an hour after injection and persistent marked stimulation the next day despite Selank co-use.

Limits. Named P21 exposure only; sequence, end groups, adamantylated modification, chemical purity and actual preparation are unverified. Do not transfer P021 mouse chemistry or cell-cycle p21 protein studies. Self-selected anonymous public reporting with no controlled comparison or independent clinical assessment; not causal proof, a population rate or established safety. All named source bodies were visible through the web tool. Guarded raw retrieval of 1qgfll6 received HTTP403 once; raw requests for the other five sources were not attempted after that host block. All full-response fingerprints remain null. Excerpt hashes are distinct from full-body/HTML hashes. Exact original publication timestamps unverified; review/index/footer/relative-age dates must not substitute. Two-day report only; usual Semax and substituted Selank are disclosed co-interventions. Acute temporal association does not establish P21 caused panic or benefits. Different-author comments about tinnitus or head heat are not assigned to this reporter or counted in this record. Three distinct publicly visible report groups are counted conservatively; anonymous people, exposures and independence cannot be independently verified.

Preparation: Publicly named P21 preparation; chemical identity, terminal modifications and purity unverified. Route: Subcutaneous explicitly stated.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Human report

P21 nasal-spray subjective clarity account

One anonymous public firsthand reporter; preparation and outcomes not independently verified.

Reported findings. Reporter perceived clearer thinking, more fluent reading/recall and calmer mood during approximately three weeks of use.

Nonresponse. Same-author comment reports apparent loss of effectiveness; stop/restart and trying Cortexin are intentions, not observed outcomes.

Harms. No harms described in inspected account; absence of reporting does not establish safety.

Limits. Named P21 exposure only; sequence, end groups, adamantylated modification, chemical purity and actual preparation are unverified. Do not transfer P021 mouse chemistry or cell-cycle p21 protein studies. Self-selected anonymous public reporting with no controlled comparison or independent clinical assessment; not causal proof, a population rate or established safety. All named source bodies were visible through the web tool. Guarded raw retrieval of 1qgfll6 received HTTP403 once; raw requests for the other five sources were not attempted after that host block. All full-response fingerprints remain null. Excerpt hashes are distinct from full-body/HTML hashes. Exact original publication timestamps unverified; review/index/footer/relative-age dates must not substitute. Original post and l3sf36d comment are one person, not independent reports. Exact elapsed time between them is unverified. No harms described in selected account; absence of a report is not evidence of safety. A separate commenter agreeing with the results is not counted as a verified independent account. Three distinct publicly visible report groups are counted conservatively; anonymous people, exposures and independence cannot be independently verified.

Preparation: Publicly named P21 preparation; chemical identity, terminal modifications and purity unverified. Route: Nasal spray explicitly stated.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Human report

P21 subcutaneous exposure: uncertain effect amid fatigue

One anonymous public firsthand reporter; preparation and outcomes not independently verified.

Reported findings. Same-author m3yqkp4 account perceived greater study persistence/stamina and easier flow while using Concerta, armodafinil and coffee, among multiple other interventions. Same-author kzje39i account reports feeling effects intranasally, without a specific clinically verified endpoint.

Nonresponse. kwsv2if reports no clear effect in about a week and no mitigation of poor focus/irritability during sleep deprivation and excessive exercise; reporter calls it inconclusive. kzje39i reports intranasal effects became less noticeable thereafter.

Harms. No harms described in inspected account; absence of reporting does not establish safety.

Limits. Named P21 exposure only; sequence, end groups, adamantylated modification, chemical purity and actual preparation are unverified. Do not transfer P021 mouse chemistry or cell-cycle p21 protein studies. Self-selected anonymous public reporting with no controlled comparison or independent clinical assessment; not causal proof, a population rate or established safety. All named source bodies were visible through the web tool. Guarded raw retrieval of 1qgfll6 received HTTP403 once; raw requests for the other five sources were not attempted after that host block. All full-response fingerprints remain null. Excerpt hashes are distinct from full-body/HTML hashes. Exact original publication timestamps unverified; review/index/footer/relative-age dates must not substitute. Three comments share a publicly visible author identity and must remain one report group. Relative-age rendering varies; no absolute chronology between comments is assumed. Other concurrent experimentation disclosed includes Cerebrolysin, Semax, Adamax, memantine, ipamorelin and CJC no DAC. Timing and contribution cannot be isolated. Muscle pain, impaired walking and sore throat in m3yqkp4 are explicitly attributed to another preparation, Cerebrolysin, and are excluded as P21 harms. m3yqkp4 offers supplier referrals; potential commercial incentive is unresolved. Retain this bias openly without reproducing prices, purchasing guidance, contact solicitation or vendor names. Three distinct publicly visible report groups are counted conservatively; anonymous people, exposures and independence cannot be independently verified.

Preparation: Publicly named P21 preparation; chemical identity, terminal modifications and purity unverified. Route: Subcutaneous explicitly stated in kwsv2if; intranasal explicitly stated in kzje39i. Route of the positive m3yqkp4 account is not clearly assigned.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Compounding

not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.

Research

investigational. Transgenic Alzheimer disease mouse models in the cited P021 paper.

Sport

unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.

Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

Risks and mix-ups already on the record

  • Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
  • No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
  • No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.

People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.

Sources

  1. P21 / Peptide 021 primary study · PMID 28655344 · checked 2026-10-09

Questions people ask

Is P21 / Peptide 021 (Supplier identity) FDA-approved?

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Does PepBear pick an amount of P21 / Peptide 021 (Supplier identity)?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

How many units is a listed P21 / Peptide 021 (Supplier identity) vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.